<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365220">
  <stage>Registered</stage>
  <submitdate>29/01/2014</submitdate>
  <approvaldate>5/02/2014</approvaldate>
  <actrnumber>ACTRN12614000133639</actrnumber>
  <trial_identification>
    <studytitle>The STRICT pilot study - Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial</studytitle>
    <scientifictitle>In metastatic colorectal cancer patients with systemic inflammation, is daily simvastatin feasible and safe to add to standard chemotherapy? </scientifictitle>
    <utrn />
    <trialacronym>The STRICT pilot study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal cancer</healthcondition>
    <healthcondition>Systemic Inflammation</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will receive standard first line chemotherapy, as chosen by their treating medical oncologist. In addition, participants will be asked to take a daily 40mg dose of simvastatin orally in the evening from the first day of chemotherapy until tumour progression or patient is withdrawn from treatment due to clinician or patient decision. 

Adherence to medication will be conducted using patient diaries, completion of a monthly Medication Adherence Record Scale-5 questionnaire, and pharmacy records. </interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Toxicity: Incidence of serious Grade 3 or 4 toxicity graded according to NCI CTCAE version 4.03</outcome>
      <timepoint>until tumour progression (anticipated to be &lt;12 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Feasibility
- recruitment rates will be assessed using screening/enrollment logs collected at each recruitment site 
- study drug adherence will be assessed using patient diaries, monthly Medicines Adherence Report Scale and pharmacy records. </outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in inflammatory biomarkers
- IL-6 and IL-8 will be assessed by plasma ELISA assays
- WBC and differential will be assessed by full blood count
- Myeloid derived suppressor cell phenotype will be assessed by whole blood flow cytometry assays
- inflammatory plasma protein will be assessed by mass spectroscopy and western blot assays.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life will be assessed by EuroQoL 5D and EORTC QolC30 questionnaires</outcome>
      <timepoint>12 weeks </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must fulfill ALL of the following criteria to be eligible for admission to the study:

* Radiological or pathologically confirmed metastatic colorectal cancer 

* Measurable or evaluable disease

* Eligible for XELOX, mFOLFOX6, or FOLFIRI plus bevacizumab in accordance with local standards of care and pharmaceutical benefits scheme approvals 

* Evidence of systemic inflammation - NLR &gt; or = 5

* WHO performance status of 0, 1 or 2

* Adequately recovered from recent surgery. At least 4 weeks must have elapsed from major surgery. 

* Life expectancy of &gt; 3 months

* Hematology performed within 28 days of starting study treatment and with values within the ranges specified below
 - Absolute granulocytes/neutrophils &gt; 1.5 x 109 /L
 - Platelets &gt; 100 x 109/L 
 - Hemoglobin &gt; 80g/L

* Biochemistry performed within 28 days of starting study treatment and with values within the ranges specified below
 - Total bilirubin &lt; 1.5 x institutional upper limit of normal (&lt; 2.0 x with documented liver metastases)
 - ALT &lt; 2.5 x institutional upper limit of normal (&lt; 5.0 x with documented liver metastases)
 - AST &lt; 2.5 x institutional upper limit of normal (&lt; 5.0 x with documented liver metastases)
 - Serum creatinine &lt; 1.5 x institutional upper limit of normal or Creatinine Clearance &gt; 50ml/min
 - Magnesium &gt; 0.5mM (1.2 mg/dL)
 - Creatine phosphokinase &lt; 2.5 x institutional upper limit of normal

* Patient must consent to provision of access to a representative formalin fixed paraffin block of tumour tissue for future research studies to be conducted. Where no previously resected or biopsied tumour tissue exists the patient may still be eligible for the study. 

* Patient must consent to provision of blood samples. 

* Age over 18 years

* Patient consent for trial participation must be obtained according to local Institutional Human Research Ethics Committee (HREC) requirements. 

* Patients must be accessible for treatment and follow-up. 

* The patient is not receiving therapy in a concurrent clinical study that involves systemic therapy or radiotherapy. The patient may enroll in biomarker studies and psychosocial studies. 

* Patient agrees not to seek statin therapy during and/or after the completion of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who fulfill any of the following criteria are not eligible for admission to the study:

* Prior chemotherapy for metastatic colorectal cancer or adjuvant chemotherapy completed in the last 6 months

* Radiotherapy within 28 days prior to enrolment or not recovered from a radiotherapy course

* A history of other malignancies with the exception of: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence for &gt; 3 years. 

* Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation). History of a significant bleeding event or felt by the investigator to be at risk of such events.

* Significant vascular disease (e.g. aortic aneurysm requiring surgical intervention).

* Peripheral arterial thrombosis or other arterial thrombotic events within 6 months
prior to commencement of study treatment.

* Inadequately controlled hypertension (defined as values consistently 150/100 mmHg despite use of at least three standard antihypertensive medications).

* Prior history of hypertensive crisis or hypertensive encephalopathy.

* Clinically significant (i.e. active) cardiovascular disease (e.g. NYHA Class II or greater congestive heart failure). 

* Pregnant or lactating females (a serum pregnancy test to be assessed within 7 days prior to study treatment, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment). 

* Women of childbearing potential (defined as &lt; 2 years after last menstruation and not surgically sterile) not using appropriate method of contraception and not willing to use an effective method of contraception during the study and for 6 months after the last dose of study medication. Oral or injectable contraceptive agents cannot be the sole method of contraception.

* Male patients must be surgically sterile or agree to use a barrier method of contraception.

* Any condition (e.g. psychological, geographical etc) that does not permit compliance with the protocol. 

* Presence of active inflammatory bowel disease, infection or rheumatological condition.

* Previous history or current evidence of rhabdomyolsis or myopathy.

* Receipt of the investigational drug, simvastatin, or member of the statin class of drugs within the last 28 days

* Receipt of regular dosing of NSAIDs for a period of 2 weeks or more (excluding 8mg dexamethasone used for preventing hypersensitivity reactions) or corticosteroids (dose &gt; 10 mg/day methylprednisolone equivalent). 

* History of allergy to simvastatin or other statin drugs. 

* Currently taking contraindicated medications of simvastatin (CYP3A4 or OATP1B1 inhibitors). Simvastatin is a CYP3A4 and OATP1B1 substrate that has demonstrated clinically relevant drug interactions with other known CYP3A4 and OATP1B1 substrates, inhibitors and inducers.  Warfarin is a weak substrate for CYP3A4 and use of warfarin as anticoagulant should be undertaken only with caution and close monitoring of INR and consideration should be given to switching the patient to low molecular weight heparin for the duration of the study. 

* Patients who are not able to swallow tablets. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>The study population are untreated metastatic CRC patients with elevated NLR &gt; or = 5. Patients will be included if they have radiologically or pathologically confirmed, metastatic CRC and meet the eligibility criteria of the study . A full blood count will be requested at the screening stage to determine whether patients have the required elevated systemic inflammation marker (NLR &gt; or =5). If eligible for the study, the patient will be invited to participate in the study.</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>All endpoints are exploratory in nature and will not be corrected for multiple statistical testing, which will be noted in all publications. 

* Recruitment rates for full study cohort and at each centre will be reported descriptively. 

* Patient study drug adherence will be reported descriptively. Correlations between the 3 methods for drug adherence will be investigated using Spearman rank correlation statistics.   
 
* Changes in NLR, CRP inflammatory cytokines, cells and proteins and lipid concentrations over the 12 weeks will be analysed using repeated measures ANOVA. 

* Toxicities will be graded using the NCI CTCAE version 4.03 . The incidence of toxicities will be summarized by type of adverse event and severity in frequency tables. No formal statistical analysis will be conducted. 

* Quality of life assessments on the EORTC QOLC30 and EQ-5D-3L will be used to derive pre-specified QoL scores according to the QoL manuals. Quality of life assessments and changes from baseline will be descriptively summarized by study visit. 

All statistical tests will be conducted using SPSS Version 20 (IBM) and using two-tailed significance level of 0.05. 
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/04/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Concord Repatriation Hospital - Concord</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>North Shore Private Hospital - St Leonards</hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <postcode>2139 - Concord Repatriation Hospital</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2065 - Royal North Shore Hospital</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>3002 - East Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>University of Sydney, NSW 2006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Northern Translational Cancer Research Unit Seed
Funding</fundingname>
      <fundingaddress>Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Hwy, St Leonards NSW 2065 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Bosch Institute (University of Sydney) Translational Grant in Aid</fundingname>
      <fundingaddress>Bosch Institute, School of Medical Sciences, The University of Sydney, NSW 2006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to assess the safety and feasibility of adding simvastatin to standard first-line chemotherapy regimens in untreated, metastatic colorectal cancer (CRC) patients with elevated inflammatory biomarkers. 

Who is it for? 
You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with metastatic colorectal cancer with evidence of systemic inflammation. You must also be eligible for standard first-line chemotherapy regimens in accordance with local standards of care and pharmaceutical benefits scheme approvals.
 
Study details 
All participants in this study will receive standard first line therapy, as chosen by their treating medical oncologist. In addition, participants will be asked to take a daily 40mg dose of simvastatin orally in the evening from the first day of chemotherapy until tumour progression or patient is withdrawn from treatment due to clinician or patient decision. 

Participants will be monitored for treatment toxicity and inflammation, and will also be asked to complete a questionnaire at 6 months to evaluate quality of life. The feasibility of the trial methods will also be evaluated in order to determine whether they could be used in a larger randomised clinical trial (RCT).</summary>
    <trialwebsite />
    <publication>KA Charles, SJ Clarke, M Michael, L Horvath, D Goldstein, C Diakos, P Blinman, AJ McLachlan, M Molloy, DC McMillan (2013). The STRICT (Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial) Study: A Phase II randomized, placebo-controlled clinical trial in metastatic colorectal cancer patients with elevated markers of inflammation. New Concepts Symposium at the Australasian Gastro-Intestinal Trial Groups Annual Scientific Meeting (Melbourne, Nov 2013).</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Local Area Health Distict HREC - CRGH</ethicname>
      <ethicaddress>Concord Repatriation General Hospital
Hospital Road
Concord, NSW 2139</ethicaddress>
      <ethicapprovaldate>31/10/2013</ethicapprovaldate>
      <hrec>HREC/13/CRGH/214</hrec>
      <ethicsubmitdate>23/09/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>North Shore Private Hospital HREC</ethicname>
      <ethicaddress>North Shore Private Hospital 
3 Westbourne Street
St Leonards, NSW 2065</ethicaddress>
      <ethicapprovaldate>28/11/2013</ethicapprovaldate>
      <hrec>NSPHEC 2013-009</hrec>
      <ethicsubmitdate>5/11/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Kellie Charles </name>
      <address>Cancer Pharmacology Laboratory School of Medical Sciences (Pharmacology) Room 306, Blackburn Building DO6 University of Sydney NSW 2006</address>
      <phone>+61 2 9036 5239</phone>
      <fax />
      <email>kellie.charles@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kellie Charles </name>
      <address>Cancer Pharmacology Laboratory School of Medical Sciences (Pharmacology) Room 306, Blackburn Building DO6 University of Sydney NSW 2006</address>
      <phone>+61 2 9036 5239</phone>
      <fax />
      <email>kellie.charles@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kellie Charles </name>
      <address>Cancer Pharmacology Laboratory School of Medical Sciences (Pharmacology) Room 306, Blackburn Building DO6 University of Sydney NSW 2006</address>
      <phone>+61 2 9036 5239</phone>
      <fax />
      <email>kellie.charles@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kellie Charles </name>
      <address>Cancer Pharmacology Laboratory School of Medical Sciences (Pharmacology) Room 306, Blackburn Building DO6 University of Sydney NSW 2006</address>
      <phone>+61 2 9036 5239</phone>
      <fax />
      <email>kellie.charles@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>